Nkarta (NKTX) Income from Continuing Operations (2019 - 2026)
Nkarta (NKTX) posted quarterly Income from Continuing Operations of 34037000.0 for Q1 2026, up 9.81% year-over-year from 30997087.43 in Q1 2025, and down 0.85% quarter-over-quarter from 33751000.0 in Q4 2025.
Nkarta (NKTX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Nkarta's Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 34037000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 9.81% year-over-year to 34037000.0; the TTM figure through Mar 2026 stood at 190453000.0 (down 42.28% YoY), while the FY2025 annual figure was 257866000.0, down 99.55% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 34037000.0, down from 33751000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 26586000.0 in Q1 2022, with the low at 180223000.0 in Q2 2023.
- The 5-year median for Income from Continuing Operations is 37738000.0 (2025), against an average of 65375411.76.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations tumbled 514.86% in 2022, then surged 82.94% in 2024.
- Nkarta's Income from Continuing Operations stood at 36080000.0 in 2022, then retreated by 20.49% to 43473000.0 in 2023, then advanced by 29.15% to 30801000.0 in 2024, then dropped by 9.58% to 33751000.0 in 2025, then retreated by 0.85% to 34037000.0 in 2026.
- Business Quant data shows NKTX's Income from Continuing Operations at 34037000.0 in Q1 2026, 33751000.0 in Q4 2025, and 60515000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | -46.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -145.95 Mn |
| Mar 31, 2026 | -34.04 Mn |
| Dec 31, 2025 | -33.75 Mn |
| Sep 30, 2025 | -60.52 Mn |
| Jun 30, 2025 | -62.15 Mn |
| Mar 31, 2025 | -37.74 Mn |
| Dec 31, 2024 | -30.80 Mn |
| Sep 30, 2024 | -34.57 Mn |
| Jun 30, 2024 | -30.75 Mn |
| Mar 31, 2024 | -60.42 Mn |
| Dec 31, 2023 | -43.47 Mn |
| Sep 30, 2023 | -169.42 Mn |
| Jun 30, 2023 | -180.22 Mn |
| Mar 31, 2023 | -36.65 Mn |
| Dec 31, 2022 | -36.08 Mn |
| Sep 30, 2022 | -88.41 Mn |
| Jun 30, 2022 | -145.81 Mn |
| Mar 31, 2022 | -26.59 Mn |
| Dec 31, 2021 | -23.97 Mn |
| Sep 30, 2021 | -39.69 Mn |